We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hemoglobin Cutoff Levels Evaluated for Anemia Among Healthy Individuals

By LabMedica International staff writers
Posted on 19 Aug 2021
Print article
Image: Blood test for hemoglobin: cutoff levels reevaluated for anemia among healthy individuals (Photo courtesy of Glovision Diagnostics).
Image: Blood test for hemoglobin: cutoff levels reevaluated for anemia among healthy individuals (Photo courtesy of Glovision Diagnostics).
Anemia, or low hemoglobin (Hb) concentration insufficient to meet an individual’s physiological needs, is the most common blood condition and affects approximately one-third of the world’s population.

Hb cutoffs to define anemia were first established in 1968 by experts who stated that, “over 95% of normal individuals are believed to show Hb levels higher than the cutoffs given” (i.e., 11.0 g/dL for children and 12.0 g/dL for non-pregnant women. These cutoffs were derived from statistical cutoffs not linked with physiological or health outcomes.

A multidisciplinary team of medical scientists led by the Centers for Disease Control and Prevention (Atlanta, GA, USA) collected and evaluated from 30 household, population-based nutrition surveys of preschool children aged six to 59 months and non-pregnant women aged 15 to 49 years during 2005 to 2016 across 25 countries. Data analysis was performed from March 2020 to April 2021.

The team evaluated the current World Health Organization (WHO, Geneva, Switzerland) Hb cutoffs for defining anemia among persons who are apparently healthy and to assess threshold validity with a biomarker of tissue iron deficiency and physiological indicator of erythropoiesis (soluble transferrin receptor [sTfR]) using multinational data. All surveys were required to have Hb, ferritin, and inflammation, to assess the appropriateness of pooling Hb fifth percentile, but other indicators (vitamin A and malaria) were included only when available. The final healthy sample was 13,445 children (39.9% of the original sample of 33 699 children; 6,750 boys [50.2%]; mean [SD] age 32.9 ±16.0 months) and 25,880 women (56.0% of the original sample of 46,251 women; mean [SD] age, 31.0 ± 9.5] years).

The investigators reported that survey-specific Hb fifth percentile among children ranged from 7.90 g/dL in Pakistan, to 11.23 g/dL the USA, and among women from 8.83 g/dL in Gujarat, India to 12.09 g/dL in the USA. Intersurvey variance around the Hb fifth percentile was low 3.5% for women and 3.6% for children. Pooled fifth percentile estimates were 9.65 g/dL for children and 10.81 g/dL for women. The Hb-for-sTfR curve demonstrated curvilinear associations with sTfR inflection points occurring at Hb of 9.61 g/dL among children and 11.01 g/dL among women. The newly calculated multinational fifth percentile estimates of hemoglobin are more than 1.0 g/dL lower than current WHO cutoffs for defining anemia in apparently healthy people. Study results persisted when using higher ferritin cutoffs to define iron deficiency.

The authors concluded that on the basis of data from more than 39,000 individuals from 25 countries examined, the current WHO hemoglobin cutoff levels for defining anemia among preschool children and non-pregnant women were found to be significantly higher than the fifth percentile of Hb in apparently healthy individuals from most countries evaluated. The study was published on August 6, 2021 in the journal JAMA Network Open.

Related Links:
Centers for Disease Control and Prevention
World Health Organization


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.